PharmGen Science

PharmGen Science Liabilities

The The Liabilities of PharmGen Science (004720.KS) as of Oct 9, 2026 is 49.11 B KRW. In the previous year, The Liabilities was 114.02 B KRW — a change of -56.93% (lower).

Liabilities

49.11 BKRW

YoY

-56.93%

Last updated:

In 2025, PharmGen Science's total liabilities amounted to 49.11 B KRW, a -56.93% difference from the 114.02 B KRW total liabilities in the previous year.

The PharmGen Science Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
41.35 B KRW
Jan 1, 2019
43.79 B KRW
Jan 1, 2020
51.97 B KRW
Jan 1, 2021
93.39 B KRW
Jan 1, 2022
110.28 B KRW
Jan 1, 2023
107.71 B KRW
Jan 1, 2024
114.02 B KRW
Jan 1, 2025
49.11 B KRW
The PharmGen Science Liabilities history
YEARLiabilitiesYoY
49.11 BKRW-56.93%
114.02 BKRW+5.86%
107.71 BKRW-2.33%
110.28 BKRW+18.08%
93.39 BKRW+79.69%
51.97 BKRW+18.69%
43.79 BKRW+5.91%
41.35 BKRW+137.26%
17.43 BKRW-37.52%
27.89 BKRW+56.78%
17.79 BKRW-18.86%
21.93 BKRW—
Access this data via the Eulerpool API
Get Free API Key

PharmGen Science Stock analysis

What does PharmGen Science do? PharmGen Science is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing PharmGen Science's Liabilities

PharmGen Science's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating PharmGen Science's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing PharmGen Science's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

PharmGen Science's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in PharmGen Science’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about PharmGen Science stock

The Liabilities of PharmGen Science is 49.11 B KRW in 2025.

The Liabilities of PharmGen Science changed from 114.02 B KRW to 49.11 B KRW, representing a -56.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities PharmGen Science since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's PharmGen Science historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — PharmGen Science

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — PharmGen Science